Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Home

Header Top Menu

  • News & Featured Stories
  • Media
  • Careers
  • Contact Us
  • Our Science

    Sub Menu 1

    • Pfizer in the UK
      • Our History
      • Pharmaceutical Sciences
      • Devices Centre of Excellence
      • Global Regulatory Affairs
      • Material Characterisation Team
      • Anti-Counterfeit Laboratory
    • Our Therapy Areas
      • Anti-Infectives
      • Inflammation and Immunology
      • Internal Medicine
      • Oncology
      • Rare Disease
      • Vaccines

    Sub Menu 2

    • Developing New Medicines
      • Clinical Trials
      • Pipeline
    • Research partnerships
      • ADDoPT
      • Innovative Target Exploration Network (ITEN)
      • INSPIRE Programme
      • Medical Research Council Collaboration
      • The Stratified Medicine Programme
      • Partnership with Regeneron for UK Biobank exome sequencing
    • Breakthroughs that change patients’ lives
    Hot Topic

    What is a Variant?

    What is a Variant
  • Products

    Sub Menu 4

    • Prescription medicines

    Sub Menu 5

    • Safety of Medicines
      • Medicines Regulation
      • Reporting Side Effects
      • Counterfeit Medicines
    Hot Topic

    How Does a Protease Inhibitor Work?

    Protease Inhibitor
  • Responsibility

    Sub Menu 7

    • Transparency
      • HCP & HCO Annual Disclosure Reports
      • Healthcare Organisation Grants
      • Research and Development Funding
      • Patient Organisation Funding and Support
    • Codes of Conduct
      • Gender Pay Gap Report
      • Environmental, Health and Safety Policy
      • Section 172 Statements
      • Pfizer UK Modern Slavery Statement
      • Pfizer UK Tax Strategy

    Sub Menu 8

    • Environmental Sustainability
      • Climate Action
      • Global Actions
      • Our Partnerships & Commitments
      • Sustainable Medicines
      • UK Actions
    • Insurance Details
    • Animal Welfare
    Hot Topic

    How Pfizer is Fighting Climate Change

    How Pfizer is Fighting Climate Change
  • UK Society

    Sub Menu 10

    • Social Investment
      • Volunteering and Fundraising
      • Medicines Donations
    • Raising Public Awareness
      • Change the Course
      • Pfizer Sponsors Science Museum Group's 'Cancer Revolution' Exhibition
      • Pfizer Sponsors the Superhero Series
      • Pfizer sponsors Science Museum exhibition 'Superbugs'
      • Pfizer at the British Science Festival
      • Turning Heads at Westminster

    Sub Menu 11

    • Science Education
      • Developing Science Talent
      • 'Superbugs Join The Fight' School Programme
      • Online Learning
        • Student Education Area
        • Teacher Resources
      • Community Lab
      • Career Talks
      • Lab in a Box
    • Pfizer Worldwide
      • Global Health Fellows
      • Global Aid and Emergency Relief
      • International Trachoma Initiative
    Hot Topic

    VacciNation: tackling health inequalities across England

    VacciNation report
  • UK Health System

    Sub Menu 16

    • Working with the NHS and other Healthcare Organisations
      • Collaborative Working
        • Collaborative Working Project between Lloyds Pharmacy and Pfizer Vaccines
        • Joint Working
      • Donations and Grants
        • Independent Medical Grants and Donations
        • Donations of Goods, Services and Benefit in Kind
        • Grants
        • Donations and Grants Enquiry Form
    • Working with Healthcare Professionals
      • FAQs: Working with Healthcare Professionals
      • Pharmacy
      • Healthcare Professionals Congress Sponsorship

    Sub Menu 17

    • Working with Patient Organisations
      • Patient Involvement in Research and Development
      • Our ongoing partnership with the UK Sepsis Trust
      • Partnering with the NIHR and young people on clinical research
    • Pfizer Healthcare Hub
      • Pfizer Healthcare Hub: 2018
      • Pfizer Healthcare Hub: 2017
      • Connect with the Hub
    Hot topic

    Putting patients at the heart of clinical trials

    Patients at heart of clinical trials
  • News & Featured Stories
  • Media
  • Careers

    Carrers

    • Search Current Vacancies
    • Apprenticeships
      • Apprenticeship Vacancies
    • Undergraduate Placements
      • Undergraduate Vacancies
    • Meet our people
    • UK Top Employer
    • How Pfizer is fostering meaningful growth for every colleague, everywhere
  • Contact Us
  • Footer links

    Footer mobile menu

    • Footer Menu
    • Footer menu
      • Contact Us
      • Cookie Policy
      • Terms of Use
      • Privacy Policy
      • Sitemap
    • Footer social item
      • Facebook
      • Twitter
      • Instagram
      • YouTube

Why putting patients first is always the right thing to do

Why putting patients first is always the right thing to do
News & Featured Stories/ Why putting patients first is always the right thing to do
12/02/2021

Dr Berkeley Phillips
Country Medical Director, Pfizer UK

A recent survey of over 1,700 patient groups around the world has revealed the true toll the Covid-19 pandemic has had on patient communities, with many individuals feeling more vulnerable, confused and uncertain about the consistency and continuity of their care.1

 

Soaring demand for charitable patient services, coupled with a staggering shortfall in patient group income, has created the perfect storm. With shops closed, fundraising events cancelled and additional pots of funding restricted, patient groups are being left with little choice but to cut back on the much-needed support they provide.

A study conducted last summer amongst members of a neurological charity coalition in the United Kingdom anticipated there would be approximately a 30% reduction in provision of patient services amongst its members, including local support activities, clinical care training and peer support groups.2 What's more, the Association of Medical Research Charities (AMRC), one of the leading funders of clinical trials in the UK, anticipates losing more than a quarter of its income this academic year.3 This puts much needed trials in jeopardy.

Now, more than ever, the life sciences industry has a responsibility to listen to the unique and changing needs of patients. We must continue to work with patient organisations on their vital work to safeguard continued access to treatment and to understand their need for holistic support ‘beyond the pill’.

Throughout the pandemic, we at Pfizer have continued to partner with patient organisations across a broad spectrum of conditions from cancer to rare diseases, ensuring patients feel equipped, informed and empowered despite the uncertainty.

At the start of the first national lockdown in March last year, it was apparent that patients across the country would be among the worst impacted by both the effects of the virus and our efforts as a society to protect those most vulnerable to it from harm. And like the patients they represent, it became clear that patient groups across the spectrum of disease areas they work in would also be significantly impacted by the pandemic – early estimates claim that UK charities will collectively lose approximately £6.4bn of income.4

Following numerous conversations with patient group representatives, we worked at pace to develop a ‘COVID relief fund’. Whilst by no means a solution to the problem at hand, our aim was to offer some relief for those organisations providing irreplaceable support to patients in the community. In some cases, our intervention helped organisations to exchange in-person meetings for digital meetings, ensuring patients continued to be able to access often much needed advice and emotional support.

Following numerous conversations with patient group representatives, we worked at pace to develop a ‘COVID relief fund’. Whilst by no means a solution to the problem at hand, our aim was to offer some relief for those organisations providing irreplaceable support to patients in the community." 

Working with patient organisations gives us the best opportunity to do this in a safe, compliant manner. Building relationships and spending time with them helps us to deliver new treatments and establish programmes that provide breakthroughs for patients and their families.

With the emergence of new innovative medicines, we increasingly rely on patient interaction at every step of the development pathway – from clinical trials through to post launch pathway development.

A good example of this is our work to involve patients in the design of our clinical trials. At Pfizer, we believe it is important that the patient community feels like a true partner - a co-creator – given they will be the end ‘user’ of any treatment or therapy should it reach the market.

As I illustrated at an ABPI event in June 2019: “A tech company would never research their next smart phone without actually talking to the people who are going to be using it. So why should we be any different?”5

Our recently commended collaboration with the National Institute of Health Research (NIHR) patient ambassador group really demonstrates this in practice.6 Reflecting on a meeting that comes to mind, my colleagues worked with the NIHR to facilitate a discussion with a group of patients with a chronic autoimmune condition called ulcerative colitis. During the workshop, patients were given an opportunity to share their experiences of living with the condition and were consulted on various parameters and the personal impact of an upcoming clinical trial.

As one of the participants remarked in a blog post after the event, “I think the Pfizer team learned a lot from us. That’s the great thing about having a conversation as opposed to filling out a form.” 7

This is exactly the type of active listening and engagement we value and will continue to prioritise on our journey to put patients first in all we do.

 

References

  1. Patient View. The perspectives of 1,720 patient groups during the Covid-19 pandemic. Sept 2020.
  2. The Neurological Alliance. The impact of COVID-19 on the health and care voluntary sector. Accessed Nov 2021.
  3. The Lancet. More support needed for UK charity-funded medical research. Nov 2020.
  4. Hanover. Covid-19: Impact on UK Patient Groups. June 2020.
  5. Pharmaphorum. Making Patient Involvement Meaningful. July 2019.
  6. Reuters Events. Pharma Awards Europe 2021 EU finalists. Accessed Nov 2021.
  7. NIHR. Creating conversations: Connecting life sciences companies and patients to improve research. Aug 2020.

 

PP-PFE-GBR-4210 / November 2021

Related Hot Topics
Patient View 2021
Pfizer UK ranked first for overall corporate reputation by PatientView Survey…
AMR Reimbursement Pilot Launch
World First Cross-Industry Initiative Launches in the Continued Fight Against…
What is a Variant
What is a Variant?
COVID-19 Vaccine Equity
Working To Reach Everyone, Everywhere
VacciNation report
VacciNation: tackling health inequalities across England
Patients at heart of clinical trials
Why putting patients at the heart of Pfizer UK’s clinical trials continues to…
Infection Management Coalition Paper
Cross-Industry Coalition Tackling ‘Hidden Pandemic’ of Antibiotic Resistant…
Blueprint for gene therapy adoption
Pfizer UK launch blueprint for the UK adoption of cell and gene therapies
Tags
COVID-19
UK Health System

Footer

  • Contact Us
  • Cookie Policy
  • Terms of Use
  • Privacy Policy
  • Sitemap

Footer aside

  • Footer Aside
    • Facebook
    • Twitter
    • Instagram
    • YouTube

Copyright © 2017-2022 Pfizer Limited. PP-PFE-GBR-4248 / Nov 2021. All rights reserved. Registered in England and Wales No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ. VAT No. GB201048427